17th Annual Asthma and Allergy Conference


2023 Educational Objectives

As of August 17, 2023.

To date, conference educational objectives are to recognize, discuss and debate the following (to be announced)

Allergy and Food Allergy

  • Be familiar with the endotypes and phenotypes of chronic rhinosinusitis.
  • Be familiar with the pathogenesis of chronic rhinosinusitis.
  • Be familiar with evidence-based treatment for chronic rhinosinusitis.
  • Discuss treatment for Chronic Spontaneous Urticaria without a clear allergic cause. 
  • Discuss early peanut introduction to prevent or mitigate severe peanut allergy. 
  • Understand SMART (single maintenance and reliever therapy) dosing for asthma. 
  • Discuss clinical approaches to patients with Allergic Contact Dermatitis (ACD), Aspirin-Exacerbated Respiratory Disease (AERD) and Penicillin allerg. 

Immune System

  • Identify general classifications of Primary Immunodeficiency Disorders (PID), also known as Inborn Errors of Immunity (IEI).
  • Learn PID/IEI presenting features, basic diagnostics and management approaches.
  • Explore mast cell complexity and capacity to release a broad range of active mediators with pro- and anti-inflammatory aspects implicated in complex pathology. 
  • Discuss the diverse pathology represented by mast cell disorders (MCDs), which may be primary, secondary to other diseases, and idiopathic.  

Respiratory and Pulmonary Disease

  • Examine unmet clinical and economic needs of patients with chronic cough and the burden on patient quality of life.
  • Explore underlying causes of chronic cough and strategies to recognize patients with the condition.
  • Review the clinical trial data regarding present and future treatment options for refractory chronic cough.
  • Explore a treatment plan for patients with chronic cough considers the type of cough, comorbidities, cost and potential new therapies.
  • Review the pathophysiology of asthma and biomarkers currently available.
  • Be exposed to novel asthma therapeutic biologics being studied in clinical trials and molecules that might be targets for the future.
  • Understand key data around the biologic agents currently approved for asthma therapy.
  • Discuss potential of emerging treat-to-target strategy in severe asthma management.
  • Describe the role and specific uses of common objective tests in evaluating dyspnea and asthma.
  • Describe strengths and limits of nitric oxide, bronchial provocation and rhinoscopy testing.
  • Be familiar with laryngeal pathologies that may complicate or may mimic asthma.
  • Understand treatment of gastroesophageal or laryngopharyngeal reflux disease in asthma context.
  • Understand treatment of postnasal drainage syndrome.
  • Identify signs potentially inconsistent with asthma with suspicion for mimic diseases. 
  • Follow working differential or process for considering asthma mimics. 
  • Develop an evidence-based timeline for follow-up based on severity and symptoms. 
  • Understand the mechanism by which obesity causes airway collapse. 
  • Recognize severity criteria for sleep disorder breathing. 
  • Review the effects of, and patient selection criteria, for hypoglossal nerve stimulation. 

Skin and Swelling

  • Review common causes of angioedema in clinical practice.
  • Distinguish histamine-driven presentations from bradykinin-based presentations (ACE-I, hereditary, acquired).
  • Become familiar with diagnosis and therapeutic options for hereditary and acquired angioedema.
  • Review current theories of pathogenesis, and the diagnostic approach, for chronic spontaneous urticaria (CSU).
  • Examine the stepwise approach to current CSU therapies.
  • Differentiate Atopic Dermatitis from mimics such as scabies, transient acantholytic dermatosis, molluscum dermatitis and psoriasis.
  • Identify clinical features and distribution that may suggest Cutaneous T cell Lymphoma.
  • Understand how contact dermatitis can produce refractory dermatitis that may mimic atopic dermatitis.
  • Identify features that facilitate diagnosis of dermatomyositis and lupus erythematosus.
  • Review features of urticarial vasculitis that help the clinician recognize this process.
  • Discuss cutaneous findings in ANCA positive vasculitis.


  • Be knowledgeable about organizational and wellness initiatives for physicians.
  • Discover and develop self-care approaches for personal wellness.